

Alzheimer's Disease Biomarkers Multiplex Detection Kit

Flow Cytometry Immunofluorescence

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, accounting for 60–80% of cases. It is characterized by the accumulation of amyloid-beta plaques and neurofibrillary tangles (Tau protein) in the brain, leading to neuronal damage, synaptic loss, and brain atrophy.

AD faces significant challenges in early diagnosis, particularly during the stages of Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), where atypical symptoms are often overlooked. Blood-based biomarker testing, with its advantages of being non-invasive, convenient, and repeatable, offers a breakthrough solution for the early screening, diagnosis, and prognosis assessment of AD.

Testing Principle

This kit utilizes flow fluorescence immunoassay technology to quantitatively measure the concentrations of phosphorylated Tau217 (pTau217), phosphorylated Tau181 (pTau181), β -amyloid 1–40 ($A\beta$ 1–40), β -amyloid 1–42 ($A\beta$ 1–42), glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and α -synuclein (α -SYN) in human plasma.



Product Features

Comprehensive Biomarkers

Covers 7 key AD biomarkers for precise diagnosis & monitoring

High Sensitivity

Detects biomarkers at pg/mL level


Patient-Friendly

Serum/plasma-based testing eliminates invasive collection

Cold Chain Free

Reagents are stable for shipping at room temperature

The brain of an Alzheimer's patient shows significant atrophy, ventricular enlargement, and the hallmark accumulation of amyloid-beta plaques and neurofibrillary tangles.



Detected Biomarkers

Biomarker & Detection Significance

pTau217	pTau181	Aβ1-42/Aβ1-40	GFAP	NfL	α-SYN
Critical Tau phosphorylation site in early AD, enabling detection of initial pathological changes and supporting early clinical intervention	Effectively differentiates AD from other neurodegenerative disorders while serving as a progression biomarker to monitor disease advancement	Reflects cerebral amyloid deposition for risk stratification, pathological burden assessment, early screening, and anti-amyloid therapy evaluation	Identifies neuroinflammatory status, assists in determining disease severity, and serves as a potential monitoring indicator	Monitors neuronal integrity for prognosis assessment and dynamic disease tracking	Evaluates synaptic dysfunction and supports differential diagnosis of neurodegenerative diseases

Platform

This kit is compatible with the BD FACSCanto™ II Clinical Flow Cytometry System, as well as other flow cytometers equipped with APC and PE fluorescence detection channels.

Ordering Information

Cat. No.	Product Name	Parameters						Kit Size	Shelf Life
		pTau217	pTau181	Aβ1-42	Aβ1-40	GFAP	NfL	α-SYN	
SF011405T2050	Alzheimer's Disease Biomarkers Multiplex Detection Kit (7-Plex)	●	●	●	●	●	●	50	12
SF011405T2025								25	
SF011406T2050	Alzheimer's Disease Biomarkers Multiplex Detection Kit (4-Plex)	●	●	●	●			50	
SF011403T2050	Alzheimer's Disease Biomarkers Multiplex Detection Kit (3-Plex)	●				●	●	50	

*Storage Temp.: 2-8°C
Shipping Temp.: Room Temperature, 10 days



Jiangsu Mole Bioscience Co., Ltd.
No.1, Lingzhi Road, Medical New & Hi-tech District
(Gaogang District), 225300 Taizhou,
Jiangsu Province, China

Tel: 0571-87209310
Email: info@molechina.com
www.molechina.com
Ver: 1.0 | Date: 2026-06-20